PDCD1LG2 and neoplasm: TMB, PD-L1 and PD-L2, and MSI in tumor tissue are believed to be potent biomarkers for predicting immunotherapy response, but the relationship between these biomarkers is complex and it remains unclear whether employing a combination of biomarkers is superior to relying on a single marker (Luchini et al., 2019; Ren et al., 2020).